{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(2)"],"submitter":["Cao Y"],"pubmed_abstract":["Current staging systems for natural killer/T cell lymphoma (NKTCL) inadequately reflect its predominantly extranodal presentation and lack prognostic accuracy in the asparaginase era. This retrospective multicenter study analyzes 1,872 newly diagnosed NKTCL patients treated with asparaginase-based regimens or radiotherapy alone, from 15 institutions across China. For nasal-type NKTCL, skull base invasion (SBI) is identified as an independent adverse prognostic factor. We reclassify Ann Arbor stage I patients with SBI as stage II and stage II patients with SBI as stage III. For non-nasal-type NKTCL, we retain the Chinese Southwest Oncology Group and Asia Lymphoma Study Group (CA) system due to its superior prognostic discrimination. The revised system demonstrates improved outcome predictio"],"journal":["Cell reports. Medicine"],"pagination":["102617"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12923967"],"repository":["biostudies-literature"],"pubmed_title":["A revised staging system for natural killer/T cell lymphoma incorporating skull base invasion and nasal/non-nasal subtype distinction."],"pmcid":["PMC12923967"],"pubmed_authors":["Jing H","Cai Q","Cai P","Zhang H","Huang H","Shuang Y","Cai J","Qi S","Peng Z","Zhao Y","Wang L","Bai S","Zou Q","Li B","Song Y","Xia Y","Nie M","Sun X","Fang X","Li Z","Zhang Y","Cao Y","Yin Q","Gao Y","Tao R","Gao X","Zhong L"],"additional_accession":[]},"is_claimable":false,"name":"A revised staging system for natural killer/T cell lymphoma incorporating skull base invasion and nasal/non-nasal subtype distinction.","description":"Current staging systems for natural killer/T cell lymphoma (NKTCL) inadequately reflect its predominantly extranodal presentation and lack prognostic accuracy in the asparaginase era. This retrospective multicenter study analyzes 1,872 newly diagnosed NKTCL patients treated with asparaginase-based regimens or radiotherapy alone, from 15 institutions across China. For nasal-type NKTCL, skull base invasion (SBI) is identified as an independent adverse prognostic factor. We reclassify Ann Arbor stage I patients with SBI as stage II and stage II patients with SBI as stage III. For non-nasal-type NKTCL, we retain the Chinese Southwest Oncology Group and Asia Lymphoma Study Group (CA) system due to its superior prognostic discrimination. The revised system demonstrates improved outcome predictio","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T14:53:47.769Z","creation":"2026-07-09T11:01:14.611Z"},"accession":"S-EPMC12923967","cross_references":{"pubmed":["41672065"],"doi":["10.1016/j.xcrm.2026.102617"]}}